Table 3A.

Cox proportional hazards models for progression-free survival (PFS) and overall survival (OS) in all patients with non-small cell lung cancer excluding PD-L1 status, according to univariate (A) and multivariate (B) analyses.

Items	PFS (Univariate Analysis)		OS (Univariate Analysis)
	HR (95% CI)	p-Value	HR (95% CI)	p-Value
Age ≥ 70	1.07 (0.62-1.88)	0.80	1.17 (0.53-2.57)	0.69
Male gender	0.69 (0.38-1.27)	0.23	1.66 (0.62-4.43)	0.31
Recurrent	0.72 (0.34-1.54)	0.40	0.38 (0.09-1.61)	0.19
ECOG-PS = 2	0.78 (0.19-3.21)	0.73	2.19 (0.52-9.30)	0.29
Smoker	0.92 (0.50-1.70)	0.79	2.13 (0.73-6.22)	0.17
PD-L1 ≥ 50%a	0.76 (0.37-1.55)	0.45	0.68 (0.25-1.82)	0.44
Brain metastasis	1.43 (0.61-3.36)	0.41	0.91 (0.21-3.86)	0.90
Liver metastasis	1.47 (0.71-3.04)	0.30	1.28 (0.48-3.42)	0.62
Pembrolizumab regimenb	0.61 (0.27-1.38)	0.23	1.06 (0.31-3.53)	0.93
Squamous Histology	1.14 (0.62-2.12)	0.67	1.27 (0.55-2.95)	0.58
With irAEs	0.53 (0.30-0.93)	0.026	0.66 (0.30-1.44)	0.29
With mild irAEs	0.45 (0.25-0.81)	0.008	0.35 (0.14-0.89)	0.027
With severe irAEs	1.37 (0.66-2.82)	0.40	2.17 (0.91-5.21)	0.08
Pneumonitis	1.05 (0.49-2.24)	0.91	1.15 (0.40-3.37)	0.79
Rash	0.74 (0.39-1.39)	0.34	0.40 (0.14-1.16)	0.09
Thyroid dysfunction	0.46 (0.17-1.29)	0.14	0.53 (0.13-2.26)	0.39
Endocrinec	0.38 (0.13-1.05)	0.06	0.46 (0.11-1.95)	0.29

^aPD-L1 TPS ≥ 50% versus all others except for unknown.

^bPembrolizumab regimen versus Atezolizumab regimen.

^cThyroid dysfunction, Adrenal insufficiency, and hypophysitis.

Mild irAEs: showing in grade 1-2 irAEs, severe irAEs: showing in grade 3-5 irAEs.

ECOG-PS, eastern cooperative oncology group performance status; PD-L1, programmed death ligand 1; irAE, immune-related adverse event.